Chalcogen Bonded Indirectly To The Five-membered Hetero Ring By Acyclic Nonionic Bonding Patents (Class 514/428)
-
Publication number: 20100256129Abstract: Provided herein are compounds of formulae I to II that bind to androgen receptors and/or modulate activity of androgen receptors; and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.Type: ApplicationFiled: December 12, 2008Publication date: October 7, 2010Inventor: Lin Zhi
-
Publication number: 20100256130Abstract: The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.Type: ApplicationFiled: May 19, 2010Publication date: October 7, 2010Inventors: Krista B. Goodman, Michael J. Neeb, Clark A. Sehon, Andrew Q. Viet, Gren Z. Wang
-
Patent number: 7807709Abstract: The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesisType: GrantFiled: March 21, 2006Date of Patent: October 5, 2010Assignee: Novartis AGInventors: Claus Ehrhardt, Osamu Irie, Edwige Liliane Lorthiois, Juergen Klaus Maibaum, Nils Ostermann, Holger Sellner
-
Patent number: 7807708Abstract: Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.Type: GrantFiled: June 25, 2007Date of Patent: October 5, 2010Assignee: Galderma Research & DevelopmentInventors: Thibaud Biadatti, Laurence Dumais, Catherine Soulet, Sandrine Talano, Sebastien Daver
-
Publication number: 20100249188Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.Type: ApplicationFiled: September 10, 2008Publication date: September 30, 2010Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
-
Publication number: 20100234349Abstract: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.Type: ApplicationFiled: September 4, 2007Publication date: September 16, 2010Inventors: Gunnar M. Olsen, Dan Peters, Bjarne H. Dahl, Jeppe Kejser Christensen, Steven Charles Loechel, Daniel B. Timmermann
-
Patent number: 7795304Abstract: The invention relates to hydroxamic acid derivatives having carbamate linkage with the structural formula that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous systems (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.Type: GrantFiled: August 22, 2005Date of Patent: September 14, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Sandro Belvedere, Christopher Laurence Hamblett, Thomas A. Miller, David J. Witter, Jiaming Yan
-
Patent number: 7795315Abstract: The present invention provides novel compounds of the general formula (I) and pharmaceutically acceptable salts thereof, processes for the manufacture of these novel compounds and medicaments containing such compounds. The compounds of the present invention show anti-proliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion. The invention also covers the use of such compounds for the treatment of diseases such as cancer and for the manufacture of corresponding medicaments.Type: GrantFiled: January 23, 2009Date of Patent: September 14, 2010Assignee: Hoffman-La Roche Inc.Inventors: Li Chen, Yun He, Jason Christopher Wong
-
Publication number: 20100222406Abstract: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R1 is selected from the group consisting of C1-C4 alkyl, hydroxy and C1-C4 alkoxy; X is selected from the group consisting of N and CH; Z is selected from the group consisting of NH, O, S and CH2; R2 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy; and R3 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy.Type: ApplicationFiled: January 14, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Lloyd S. Gray, Doris M. Haverstick
-
Patent number: 7786150Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: May 14, 2009Date of Patent: August 31, 2010Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20100216837Abstract: The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.Type: ApplicationFiled: December 21, 2005Publication date: August 26, 2010Applicant: GLAXO GROUP LIMITEDInventors: Andrea Bozzoli, Daniel Marcus Bradley, Steven Coulton, Martin Leonard Gilpin, Jacqueline Anne MacRitchie, Roderick Alan Porter, Kevin Michael Thewlis
-
Publication number: 20100215774Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 8, 2008Publication date: August 26, 2010Inventor: Todd Maibach
-
Publication number: 20100216776Abstract: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon activation of the S100 protein, where the fluorescent dye has decreased fluorescence when exposed to the aqueous solution than when protected from exposure to the aqueous solution. Also provided are methods of treating a subject having metastatic cancer.Type: ApplicationFiled: August 10, 2006Publication date: August 26, 2010Inventors: Anne Reba Bresnick, Sarah Claire Garrett
-
Patent number: 7776910Abstract: Compounds of the formula I: wherein m, n, Ar, R1 and R2 are as defined herein. Methods of making the compounds and using the compounds are disclosed.Type: GrantFiled: November 8, 2007Date of Patent: August 17, 2010Assignee: Roche Palo Alto LLCInventors: Francisco Javier Lopez-Tapia, Lee Edwin Lowrie, Jr., Dov Nitzan
-
Publication number: 20100197626Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.Type: ApplicationFiled: May 8, 2007Publication date: August 5, 2010Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Publication number: 20100190792Abstract: Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds (I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII).Type: ApplicationFiled: February 26, 2008Publication date: July 29, 2010Inventors: John E. Donello, Fabien J. Schweighoffer, Lauren M. Luhrs
-
Publication number: 20100189698Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.Type: ApplicationFiled: June 30, 2008Publication date: July 29, 2010Applicant: CLARENCEW PTY LTDInventor: Gregory Lynn Willis
-
Publication number: 20100189818Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: January 19, 2010Publication date: July 29, 2010Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: GUOCHUAN EMIL TSAI
-
Publication number: 20100184727Abstract: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.Type: ApplicationFiled: June 7, 2007Publication date: July 22, 2010Applicant: SUMMIT (CAMBRIDGE) LIMITEDInventors: Alan Geoffrey Roach, Paul Goldsmith
-
Publication number: 20100160298Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy.Type: ApplicationFiled: February 8, 2010Publication date: June 24, 2010Applicant: Alcon Research, Ltd.Inventors: Peter G. Klimko, Clay Beauregard
-
Patent number: 7741364Abstract: The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.Type: GrantFiled: June 27, 2007Date of Patent: June 22, 2010Assignee: Abbott LaboratoriesInventors: Ramin Faghih, Gregory A. Gfesser, Christopher L. Lynch, Murali Gopalakrishnan, Sujatha Gopalakrishnan, John Malysz, Earl J. Gubbins, Rachid El Kouhen, Jinhe Li
-
Publication number: 20100152236Abstract: A compound represented by the formula (I) wherein ring A is a 5- to 8-membered ring optionally having further substituent(s) other than R6, R7 and R8, R1 is an electron-withdrawing group, R2, R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R6 is a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R7 is a cyano group, a nitro group, an acyl group optionally having substituent(s), an optionally esterified or amidated carboxyl group or a hydrocarbon group optionally having substituent(s), or R6 and R7 optionally form, together with the carbon atom bonded thereto, a ring optionally having substituent(s), and R8 is a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygType: ApplicationFiled: August 1, 2006Publication date: June 17, 2010Applicant: Takeda Pharmaceutical Company LimitedInventors: Satoshi Yamamoto, Atsushi Hasuoka
-
Publication number: 20100144720Abstract: Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.Type: ApplicationFiled: December 11, 2009Publication date: June 10, 2010Applicant: ChemoCentryx, Inc.Inventors: Anita Melikian, Jennifer Burns, Brian E. McMaster, Thomas Schall, John J. Wright
-
Patent number: 7728032Abstract: A chemical genus of biphenyl heterocycle derivative inhibitors of LTA4H (leukotriene A4 hydrolase) of the formula: is disclosed. In these compounds Q and Z are (CH2)1-10; in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(?O)— or —C?O(NH)—; Het is a 5-7 membered non-aromatic nitrogen heterocycle; and W is acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl, or substituted heterocyclyl, or taken together ZW can be H or —COOalkyl. The compounds are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.Type: GrantFiled: August 2, 2007Date of Patent: June 1, 2010Assignee: deCODE genetics ehfInventors: Vincent Sandanayaka, Pushpa Chandrasekar, Mark E. Gurney
-
Publication number: 20100129311Abstract: The present invention relates to new phenylalanine amide inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Patent number: 7723377Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and Alzheimer's disease with a derivative of ginger oil are also provided. Also provided is a method of conditioning biological extracts, such as a medicinal plant extract, by a reductive amination process to give nitrogen-containing derivatives.Type: GrantFiled: September 28, 2007Date of Patent: May 25, 2010Assignee: Cognition Therapeutics, Inc.Inventors: Gilbert M Rishton, Hiromi Arai, Zoya Kai, Cody Lee Fullenwider, Kristin Beierle
-
Publication number: 20100125076Abstract: Substituted sulphonamides having the general formula (I) and salts, hydrates and solvates thereof were prepared and described, wherein R1 is CO or SO2 and R2 is NH or O and where R represents linear or cyclic aliphatic chain and n represents number of linking aliphatic chain carbons (n can be 0, 1, 2 or 3), which are useful in the manufacture of the medicaments due to the carboanhydrase inhibition. These compounds are prepared by nucleophilic reaction of an amine with 4-sulfamoylbenzenesulphonyl chloride in the presence of triethylamine excess in tetrahydrofurane or in ether at temperature 0 to 20° C. The compounds show an antiglaucomatic activity.Type: ApplicationFiled: April 20, 2008Publication date: May 20, 2010Applicant: Unimed Pharma, Spol. S R.O.Inventors: Fridrich Gregan, Milan Remko, Elena Sluciakova, Jarmila Knapikova
-
Publication number: 20100120615Abstract: The present invention relates to 4-cycloalkyl- or 4-aryl-substituted phenoxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.Type: ApplicationFiled: March 8, 2008Publication date: May 13, 2010Applicant: BAYER CROPSCIENCE AGInventors: Klaus Kunz, Ralf Dunkel, Jörg Nico Greul, Oliver Guth, Kerstin Ilg, Darren James Mansfield, Wahed Ahmed Moradi, Thomas Seitz, Peter Dahmen, Ulrike Wachendorff-Neumann, Arnd Voerste, Jean-Pierre Vors
-
Publication number: 20100105687Abstract: Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of the following formula, Formula (2), wherein the variables have the meaning defined in the specification.Type: ApplicationFiled: February 26, 2008Publication date: April 29, 2010Applicant: ALLERGAN, INC.Inventors: John E. Donello, Fabien J. Schweighoffer, Lauren M. Luhrs
-
Publication number: 20100105671Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.Type: ApplicationFiled: August 7, 2009Publication date: April 29, 2010Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
-
Publication number: 20100105755Abstract: The present invention relates to new substituted benzamide modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 11, 2009Publication date: April 29, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7705001Abstract: Disclosed herein is a compound comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: March 17, 2009Date of Patent: April 27, 2010Assignee: Allergan, IncInventor: David W. Old
-
Publication number: 20100099669Abstract: Provided herein are methods of treating gastrointestinal motility disorders by targeting the dopamine 3 receptor (D3R). A D3R agonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. A D3R antagonist is administered to a subject to decrease gastrointestinal motility to treat the disorder.Type: ApplicationFiled: December 21, 2009Publication date: April 22, 2010Inventors: Pankaj Jay Pasricha, Maria-Adelaide Micci
-
Publication number: 20100099738Abstract: Polyethylene glycol (PEG)-lipid conjugates, polyethylene glycol (PEG)-lipid conjugate based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.Type: ApplicationFiled: September 10, 2009Publication date: April 22, 2010Applicant: ABBOTT LABORATORIESInventors: Todd M. Hansen, Robert D. Hubbard, Leiming Li, Lu Tian, Carol K. Wada, Xiaobin Zhao
-
Publication number: 20100099741Abstract: Described herein are methods for identification of alternative safe molecular targets and novel regulators in complex molecular networks using a novel fault diagnosis engineering approach. For example, in this invention we claim new molecular targets that could be effectively targeted for changing the activity of CREB, and therefore for treatment of learning and memory related disorders. Learning and memory dysfunction is a major clinical manifestation of a number of human disorders, such as Alzheimer Disease (AD), schizophrenia, dementias, autism, etc. More specifically, we claim that composition and compounds that can target the activity of L AND/OR P/Q-, N-type calcium channels, G?i, G??, PP2A and CaMKII and IV are effective therapeutics for the treatment of disorders manifested by learning and memory dysfunction.Type: ApplicationFiled: October 20, 2009Publication date: April 22, 2010Inventor: Effat Emamian
-
Patent number: 7700585Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: GrantFiled: April 30, 2007Date of Patent: April 20, 2010Assignee: sanofi-aventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Nathalie Rakotoarisoa
-
Patent number: 7700587Abstract: Haloperidol analogs that conforms to the structural formulae: wherein: R is H, or —(CH2)n—OH, n is an integer from 0 to 2, and A is a heterocyclic bridging group, consisting essentially of carbon and at least one nitrogen atom, which effectively maintains the distance between the moieties connected thereby such that the compound (1) is incapable of metabolizing to BCPP+ like species, (2) has an affinity for the D2 receptor subtype of 15<D2<250 and (3) functions as a dopamine receptor antagonist, or the structural formulae: wherein: R1 is H, or —(CH2)n—OH, n is an integer from 0 to 2, B is an aza- or diaza-bicyclo group, which effectively maintains the distance between the moieties connected thereby such that the compound is incapable of metabolizing to BCPP+ like species; and Z is —CH— or N; and pharmaceutically acceptable salts, esters, derivatives, metal complexes, conjugates and prodrugs thereof.Type: GrantFiled: September 7, 2004Date of Patent: April 20, 2010Assignee: Florida A&M UniversityInventors: Seth Y. Ablordeppey, Donald M. N. Sikazwe
-
Patent number: 7687504Abstract: A compound of the following formula: wherein R1 R2, R3, R4, R5, R6, W, X, Y, Z, m, n, and p are as defined herein. This invention also covers methods for inhibiting dipeptidyl peptidase IV or VIII, or treating Type II diabetes with such a compound.Type: GrantFiled: March 9, 2005Date of Patent: March 30, 2010Assignee: National Health Research InstitutesInventors: Weir-Torn Jiaang, Xin Chen, Su-Ying Wu, Yu-Sheng Chao, Hsing-Pang Hsieh
-
Patent number: 7687525Abstract: The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.Type: GrantFiled: November 14, 2007Date of Patent: March 30, 2010Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Tsuneji Suzuki, Tomoyuki Ando, Katsutoshi Tsuchiya, Osamu Nakanishi, Akiko Saito, Takashi Yamashita, Yoshinori Shiraishi, Eishi Tanaka
-
Publication number: 20100068280Abstract: Pharmaceutical compositions comprising phenylephrine in a sustained release oral dosage formulation. Compositions can comprise phenylephrine alone or phenylephrine in combination additional pharmaceutically active substances such as an antihistamine and/or an analgesic.Type: ApplicationFiled: June 1, 2007Publication date: March 18, 2010Inventor: John W. PATTON
-
Publication number: 20100048531Abstract: The present invention relates to a compound of formula I wherein R1, R2, X, Ar1 and Ar2 are as defined herein and to pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to their corresponding enantiomers and/or optical isomers thereof. Compounds of the invention are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.Type: ApplicationFiled: August 14, 2009Publication date: February 25, 2010Inventors: Sabine Kolczewski, Robert Narquizian, Emmanuel Pinard
-
Publication number: 20100035929Abstract: Disclosed are dispyrin analogue compounds useful as H3 receptor activity modulators, methods of making same, pharmaceutical compositions comprising same, and methods of treating neurological and psychiatric disorders associated with histamine H3 receptor activity using same. In one aspect, the disclosed analogues can have a structure represented by a formula: This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: June 8, 2009Publication date: February 11, 2010Inventors: Craig W. Lindsley, P. Jeffrey Conn, J. Phillip Kennedy, John T. Brogan
-
Publication number: 20100035959Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.Type: ApplicationFiled: April 29, 2009Publication date: February 11, 2010Applicant: ENZO THERAPEUTICS, INC.C/O ENZO BIOCHEM, INC.Inventors: Robert Elliot Zipkin, Sarah Spiegel, Jeffrey Kroll Adams
-
Publication number: 20100035881Abstract: The invention provides a novel wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-?-alanine, other specific ?-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific ?-alanine derivatives and the salts thereof was developed.Type: ApplicationFiled: September 15, 2006Publication date: February 11, 2010Applicant: SHISEIDO COMPANY, LTD.Inventors: Mikiko Kaminuma, Masaru Suetsugu, Makoto Tsunenaga, Kiyotaka Hasegawa, Shinji Inomata
-
Patent number: 7659306Abstract: The invention discloses the administration of nafadotride partially reverse the effect of dopamine on gastric emptying in patients suffering from gastroesophageal reflux.Type: GrantFiled: November 3, 2005Date of Patent: February 9, 2010Assignee: The Board of Regents of the University of Texas SystemInventors: Pankaj Jay Pasricha, Maria-Adelaide Micci
-
Publication number: 20100022511Abstract: A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.Type: ApplicationFiled: September 5, 2008Publication date: January 28, 2010Inventors: Fang-Yu Liu, Zhi-qun Shen
-
Publication number: 20100022616Abstract: In one aspect, the invention relates to compounds of formula I: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: July 23, 2009Publication date: January 28, 2010Inventors: Eric Stangeland, Priscilla Van Dyke, Timothy J. Church, Lori Jean Patterson, Daisuke Roland Saito
-
Publication number: 20100016374Abstract: Compounds of formula (I) and salts and solvates are provided: wherein R2 is selected from phenyl substituted with n R1 groups, and pyridyl substituted with n R1 groups; n=0, 1 or 2; each R1 is independently selected from the group consisting of halo, C1-4alkyl, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy and cyano; R3 is selected from hydrogen and C1-2 alkyl; R4 is selected from the group consisting of ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl; or R3 and R4 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocyclic ring optionally substituted with one or more groups X; each X is independently selected from the group consisting of C1-4alkyl, and haloC1-4alkyl; R12 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl and methylthio; R13 is selected from hydrogen, chloro and trifluoromethyl; R14 is selected from hydrogen, trifluoromethyl and chloro; R15 is selected from hydrogen, chloro and trifluoromethyl; R16 is selectedType: ApplicationFiled: April 3, 2007Publication date: January 21, 2010Inventors: Steven Coulton, Martin Gilpin, Roderick Alan Porter
-
Patent number: 7649011Abstract: Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.Type: GrantFiled: December 22, 2003Date of Patent: January 19, 2010Assignee: Chemocentryx, Inc.Inventors: Anita Melikian, Jennifer Burns, Brian E. McMaster, Thomas Schall, J. J. Wright
-
Publication number: 20090326039Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.Type: ApplicationFiled: March 2, 2009Publication date: December 31, 2009Applicant: The Regents Of The University Of CaliforniaInventors: Bruce D. Hammock, In-Hae Kim, Christophe Morisseau, Takaho Watanabe, John W. Newman